PYC Therapeutics Limited (ASX:PYC)

Australia flag Australia · Delayed Price · Currency is AUD
1.440
0.00 (0.00%)
Jul 11, 2025, 4:10 PM AEST
Market Cap 839.90M
Revenue (ttm) 24.99M
Net Income (ttm) -48.20M
Shares Out 583.26M
EPS (ttm) -0.11
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,374,553
Average Volume 1,016,556
Open 1.450
Previous Close 1.440
Day's Range 1.420 - 1.450
52-Week Range 0.891 - 2.080
Beta 0.55
RSI 70.94
Earnings Date Aug 29, 2025

About PYC Therapeutics

PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program which is Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for the treatment of blinding eye disease; PYC-002 a drug program for the treatment of a severe neurodevelopmental disorder; and PYC-003, which is indicated to treat autosomal dominant polycystic kidney disease. PYC Therapeuti... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Employees 5
Stock Exchange Australian Securities Exchange
Ticker Symbol PYC
Full Company Profile

Financial Performance

In 2024, PYC Therapeutics's revenue was 22.06 million, an increase of 39.56% compared to the previous year's 15.81 million. Losses were -37.73 million, 65.5% more than in 2023.

Financial Statements

News

There is no news available yet.